Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)
ID: 356364Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356364

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-031.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity through the Small Research Grant Program (R03) aimed at supporting junior faculty researchers in low- and middle-income countries (LMICs) who are focused on aging, Alzheimer's Disease (AD), and AD-related dementias (ADRD). This initiative encourages applications from eligible institutions within LMICs, with the objective of fostering research capacity and career development for junior investigators in these regions. Given the projected increase in older populations and the rising incidence of AD/ADRD in LMICs, this program is critical for addressing global health challenges. Interested applicants can apply for grants of up to $100,000 per year, with a submission deadline of February 14, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-031-Full-Announcement.html
    RFA-AG-25-031.html
    The Department of Health and Human Services, through the National Institutes of Health, has announced a funding opportunity aimed at enhancing aging and Alzheimer's Disease (AD) research in low- and middle-income countries (LMICs). The Small Research Grant Program (R03) encourages applications from junior faculty in LMICs to support their research endeavors focused on aging, AD, and AD-related dementias (ADRD). The initiative is aligned with the projected increase in older populations and the associated rise in AD/ADRD cases in LMICs, which constitutes a critical global health challenge. Eligible applicants are required to collaborate with a senior investigator and must hold academic appointments within LMIC institutions. Projects can involve pilot studies, secondary data analysis, or methodology development over a two-year period, with budgets capped at $100,000 per year. The program aims to build research capacity, foster significant contributions to scientific knowledge, and develop the next generation of researchers in the field. Key submission dates include an application deadline of February 15, 2025. Overall, this funding opportunity seeks to advance scientific understanding and support global aging research in underserved regions.
    Similar Opportunities
    Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries," aimed at fostering collaborative research on Alzheimer's disease (AD) and related dementias (ADRD) in low- and middle-income countries (LMICs). This initiative seeks to build sustainable neuroscience research capacity by encouraging partnerships between U.S. researchers and scientists from LMICs, focusing on population-relevant studies that address the unique epidemiological and risk factors associated with AD/ADRD in diverse populations. The program will provide a total of $2.16 million for up to five awards, with individual application budgets capped at $400,000 annually over a five-year period. Interested applicants must submit their proposals by February 14, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research in Low- and Middle-Income Countries (LMICs) (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for a Coordinating Center to support research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Low- and Middle-Income Countries (LMICs) through a U24 Cooperative Agreement. The primary objective of this initiative is to enhance collaboration among researchers by providing administrative coordination, stakeholder engagement, and facilitating data sharing in accordance with NIH policies, thereby addressing the growing burden of AD/ADRD in these regions. This funding opportunity is crucial for improving research accessibility and fostering sustainable programs that can lead to effective prevention and treatment strategies tailored to LMIC populations. Interested applicants can apply for a budget of up to $560,000, with proposals due by 5:00 PM on November 14, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" grant, aimed at advancing research on Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity seeks to support high-priority research initiatives that address the growing public health crisis posed by these conditions, particularly among older adults. Eligible applicants include a diverse range of entities such as educational institutions, non-profits, and tribal governments, with funding decisions based on the scientific merit of proposals and the qualifications of the investigators. Applications are due by November 12, 2024, and interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the "Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)" grant, aimed at fostering innovative research collaborations between U.S. institutions and scientists in low- and middle-income countries (LMICs). This initiative seeks to address a range of neurological, mental, and behavioral disorders by encouraging partnerships that enhance research capacity and develop culturally sensitive interventions tailored to the unique challenges faced by these regions. The program emphasizes the importance of addressing socioeconomic factors impacting health outcomes and aims to build sustainable research frameworks to tackle neuro-health issues across the lifespan. Interested applicants must submit their proposals by December 9, 2024, and can find additional information and application guidelines at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.